Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer
OBJECTIVE To assess the effects of androgen deprivation therapy (ADT) on whole‐body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease. PATIENTS AND METHODS Seventy‐two men aged 44–88 years underwent spine, hip and whole‐body dual‐energy X‐ray absorpti...
Gespeichert in:
| Veröffentlicht in: | BJU international 2008-07, Vol.102 (1), p.44-47 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 47 |
|---|---|
| container_issue | 1 |
| container_start_page | 44 |
| container_title | BJU international |
| container_volume | 102 |
| creator | Galvão, Daniel A. Spry, Nigel A. Taaffe, Dennis R. Newton, Robert U. Stanley, John Shannon, Tom Rowling, Chris Prince, Richard |
| description | OBJECTIVE
To assess the effects of androgen deprivation therapy (ADT) on whole‐body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease.
PATIENTS AND METHODS
Seventy‐two men aged 44–88 years underwent spine, hip and whole‐body dual‐energy X‐ray absorptiometry scans at baseline and after 36 weeks of ADT. The change in whole‐body and regional lean mass (LM), fat mass (FM), and bone mineral content and density (BMD) were determined. In addition, the prostate specific antigen (PSA), serum testosterone and haemoglobin levels were measured, and the level of physical activity and fatigue assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐30.
RESULTS
The upper limb, lower limb, trunk and whole‐body LM decreased by a mean (sem) of 5.6 (0.6)%, 3.7 (0.5)%, 1.4 (0.5)% and 2.4 (0.4)% (P |
| doi_str_mv | 10.1111/j.1464-410X.2008.07539.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69223469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69223469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4639-bde2f8b6928ba623f540532d64406f2473dff1601c2d1cdf37602000422330073</originalsourceid><addsrcrecordid>eNqNkMlu2zAQQIkiRbO0v1Dw0pxiZbiIlg49JEa2wkAvNdAbQVFDV44Wh5Rh-xYgf5ovKVW7zjW8kOC82R4hlEHC4rlcJEwqOZIMficcIEtgnIo82XwgJ4fA0f835OqYnIawAIgfKv1EjlkmhFKgToib_DHtHAOtWtqsgq3xgjrTU9OWtOhapI0JgRrXo6dCvT6_rBEfA-1cDGyqxtQD6bs5trSoO_toSqSu83Tpu9CbHqk1rUX_mXx0pg74ZX-fkdntza_J_Wj68-5hcjUdWalEPipK5C4rVM6zwiguXCohFbxUUoJyXI5F6RxTwCwvmS2dGCuI-4PkXAiAsTgj57u6sf_TCkOvmypYrGvTYrcKOlbmQqo8gtkOtHHQ4NHppY_r-K1moAfHeqEHfXpQqQfH-p9jvYmpX_c9VkWD5VviXmoEvu0BE6ypnY8KqnDgOMSlZJpF7vuOW1c1bt89gL7-MRte4i9bfZc3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69223469</pqid></control><display><type>article</type><title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Galvão, Daniel A. ; Spry, Nigel A. ; Taaffe, Dennis R. ; Newton, Robert U. ; Stanley, John ; Shannon, Tom ; Rowling, Chris ; Prince, Richard</creator><creatorcontrib>Galvão, Daniel A. ; Spry, Nigel A. ; Taaffe, Dennis R. ; Newton, Robert U. ; Stanley, John ; Shannon, Tom ; Rowling, Chris ; Prince, Richard</creatorcontrib><description>OBJECTIVE
To assess the effects of androgen deprivation therapy (ADT) on whole‐body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease.
PATIENTS AND METHODS
Seventy‐two men aged 44–88 years underwent spine, hip and whole‐body dual‐energy X‐ray absorptiometry scans at baseline and after 36 weeks of ADT. The change in whole‐body and regional lean mass (LM), fat mass (FM), and bone mineral content and density (BMD) were determined. In addition, the prostate specific antigen (PSA), serum testosterone and haemoglobin levels were measured, and the level of physical activity and fatigue assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐30.
RESULTS
The upper limb, lower limb, trunk and whole‐body LM decreased by a mean (sem) of 5.6 (0.6)%, 3.7 (0.5)%, 1.4 (0.5)% and 2.4 (0.4)% (P < 0.01), respectively, while FM increased by 20.7 (3.3)%, 18.7 (2.7)%, 12.0 (2.5)% and 13.8 (2.3)% (P < 0.001). Hip, spine, whole‐body and upper limb BMD decreased by 1.5 (0.5)%, 3.9 (0.4)%, 2.4 (0.3)% and 1.3 (0.3%) (P < 0.001), but not lower limb BMD. Serum testosterone, PSA and haemoglobin levels decreased by 93.3 (0.4)%, 98.2 (0.5)%, and 8.8 (0.9)% (P < 0.001), respectively. In addition, physical activity levels decreased and levels of fatigue increased.
CONCLUSION
After 36 weeks of ADT there was a significant decrease in whole‐body and regional LM and bone mass, while whole‐body and regional FM increased in older men with prostate cancer. Strategies to counteract changes in soft tissue and bone mass during ADT should be formulated to minimize the risk of sarcopenia, osteoporosis and obesity.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2008.07539.x</identifier><identifier>PMID: 18336606</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Absorptiometry, Photon ; Adipose Tissue - drug effects ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Androgen Antagonists - adverse effects ; androgen deprivation therapy ; Androgens - metabolism ; Antineoplastic Agents, Hormonal - adverse effects ; Biological and medical sciences ; Body Composition - drug effects ; Body Mass Index ; Bone Density - drug effects ; bone mass ; Cohort Studies ; fat mass ; Gynecology. Andrology. Obstetrics ; Humans ; lean mass ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Muscle, Skeletal - drug effects ; Nephrology. Urinary tract diseases ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - complications ; Prostatic Neoplasms - drug therapy ; Quality of Life ; Risk Factors ; Testosterone - metabolism ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2008-07, Vol.102 (1), p.44-47</ispartof><rights>2008 THE AUTHORS. JOURNAL COMPILATION © 2008 BJU INTERNATIONAL</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4639-bde2f8b6928ba623f540532d64406f2473dff1601c2d1cdf37602000422330073</citedby><cites>FETCH-LOGICAL-c4639-bde2f8b6928ba623f540532d64406f2473dff1601c2d1cdf37602000422330073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2008.07539.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2008.07539.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20405458$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18336606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galvão, Daniel A.</creatorcontrib><creatorcontrib>Spry, Nigel A.</creatorcontrib><creatorcontrib>Taaffe, Dennis R.</creatorcontrib><creatorcontrib>Newton, Robert U.</creatorcontrib><creatorcontrib>Stanley, John</creatorcontrib><creatorcontrib>Shannon, Tom</creatorcontrib><creatorcontrib>Rowling, Chris</creatorcontrib><creatorcontrib>Prince, Richard</creatorcontrib><title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>OBJECTIVE
To assess the effects of androgen deprivation therapy (ADT) on whole‐body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease.
PATIENTS AND METHODS
Seventy‐two men aged 44–88 years underwent spine, hip and whole‐body dual‐energy X‐ray absorptiometry scans at baseline and after 36 weeks of ADT. The change in whole‐body and regional lean mass (LM), fat mass (FM), and bone mineral content and density (BMD) were determined. In addition, the prostate specific antigen (PSA), serum testosterone and haemoglobin levels were measured, and the level of physical activity and fatigue assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐30.
RESULTS
The upper limb, lower limb, trunk and whole‐body LM decreased by a mean (sem) of 5.6 (0.6)%, 3.7 (0.5)%, 1.4 (0.5)% and 2.4 (0.4)% (P < 0.01), respectively, while FM increased by 20.7 (3.3)%, 18.7 (2.7)%, 12.0 (2.5)% and 13.8 (2.3)% (P < 0.001). Hip, spine, whole‐body and upper limb BMD decreased by 1.5 (0.5)%, 3.9 (0.4)%, 2.4 (0.3)% and 1.3 (0.3%) (P < 0.001), but not lower limb BMD. Serum testosterone, PSA and haemoglobin levels decreased by 93.3 (0.4)%, 98.2 (0.5)%, and 8.8 (0.9)% (P < 0.001), respectively. In addition, physical activity levels decreased and levels of fatigue increased.
CONCLUSION
After 36 weeks of ADT there was a significant decrease in whole‐body and regional LM and bone mass, while whole‐body and regional FM increased in older men with prostate cancer. Strategies to counteract changes in soft tissue and bone mass during ADT should be formulated to minimize the risk of sarcopenia, osteoporosis and obesity.</description><subject>Absorptiometry, Photon</subject><subject>Adipose Tissue - drug effects</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Antagonists - adverse effects</subject><subject>androgen deprivation therapy</subject><subject>Androgens - metabolism</subject><subject>Antineoplastic Agents, Hormonal - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Body Composition - drug effects</subject><subject>Body Mass Index</subject><subject>Bone Density - drug effects</subject><subject>bone mass</subject><subject>Cohort Studies</subject><subject>fat mass</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>lean mass</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - complications</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Quality of Life</subject><subject>Risk Factors</subject><subject>Testosterone - metabolism</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMlu2zAQQIkiRbO0v1Dw0pxiZbiIlg49JEa2wkAvNdAbQVFDV44Wh5Rh-xYgf5ovKVW7zjW8kOC82R4hlEHC4rlcJEwqOZIMficcIEtgnIo82XwgJ4fA0f835OqYnIawAIgfKv1EjlkmhFKgToib_DHtHAOtWtqsgq3xgjrTU9OWtOhapI0JgRrXo6dCvT6_rBEfA-1cDGyqxtQD6bs5trSoO_toSqSu83Tpu9CbHqk1rUX_mXx0pg74ZX-fkdntza_J_Wj68-5hcjUdWalEPipK5C4rVM6zwiguXCohFbxUUoJyXI5F6RxTwCwvmS2dGCuI-4PkXAiAsTgj57u6sf_TCkOvmypYrGvTYrcKOlbmQqo8gtkOtHHQ4NHppY_r-K1moAfHeqEHfXpQqQfH-p9jvYmpX_c9VkWD5VviXmoEvu0BE6ypnY8KqnDgOMSlZJpF7vuOW1c1bt89gL7-MRte4i9bfZc3</recordid><startdate>200807</startdate><enddate>200807</enddate><creator>Galvão, Daniel A.</creator><creator>Spry, Nigel A.</creator><creator>Taaffe, Dennis R.</creator><creator>Newton, Robert U.</creator><creator>Stanley, John</creator><creator>Shannon, Tom</creator><creator>Rowling, Chris</creator><creator>Prince, Richard</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200807</creationdate><title>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</title><author>Galvão, Daniel A. ; Spry, Nigel A. ; Taaffe, Dennis R. ; Newton, Robert U. ; Stanley, John ; Shannon, Tom ; Rowling, Chris ; Prince, Richard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4639-bde2f8b6928ba623f540532d64406f2473dff1601c2d1cdf37602000422330073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Absorptiometry, Photon</topic><topic>Adipose Tissue - drug effects</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Antagonists - adverse effects</topic><topic>androgen deprivation therapy</topic><topic>Androgens - metabolism</topic><topic>Antineoplastic Agents, Hormonal - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Body Composition - drug effects</topic><topic>Body Mass Index</topic><topic>Bone Density - drug effects</topic><topic>bone mass</topic><topic>Cohort Studies</topic><topic>fat mass</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>lean mass</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - complications</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Quality of Life</topic><topic>Risk Factors</topic><topic>Testosterone - metabolism</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galvão, Daniel A.</creatorcontrib><creatorcontrib>Spry, Nigel A.</creatorcontrib><creatorcontrib>Taaffe, Dennis R.</creatorcontrib><creatorcontrib>Newton, Robert U.</creatorcontrib><creatorcontrib>Stanley, John</creatorcontrib><creatorcontrib>Shannon, Tom</creatorcontrib><creatorcontrib>Rowling, Chris</creatorcontrib><creatorcontrib>Prince, Richard</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galvão, Daniel A.</au><au>Spry, Nigel A.</au><au>Taaffe, Dennis R.</au><au>Newton, Robert U.</au><au>Stanley, John</au><au>Shannon, Tom</au><au>Rowling, Chris</au><au>Prince, Richard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2008-07</date><risdate>2008</risdate><volume>102</volume><issue>1</issue><spage>44</spage><epage>47</epage><pages>44-47</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>OBJECTIVE
To assess the effects of androgen deprivation therapy (ADT) on whole‐body and regional muscle, fat and bone mass in men with prostate cancer without metastatic bone disease.
PATIENTS AND METHODS
Seventy‐two men aged 44–88 years underwent spine, hip and whole‐body dual‐energy X‐ray absorptiometry scans at baseline and after 36 weeks of ADT. The change in whole‐body and regional lean mass (LM), fat mass (FM), and bone mineral content and density (BMD) were determined. In addition, the prostate specific antigen (PSA), serum testosterone and haemoglobin levels were measured, and the level of physical activity and fatigue assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐30.
RESULTS
The upper limb, lower limb, trunk and whole‐body LM decreased by a mean (sem) of 5.6 (0.6)%, 3.7 (0.5)%, 1.4 (0.5)% and 2.4 (0.4)% (P < 0.01), respectively, while FM increased by 20.7 (3.3)%, 18.7 (2.7)%, 12.0 (2.5)% and 13.8 (2.3)% (P < 0.001). Hip, spine, whole‐body and upper limb BMD decreased by 1.5 (0.5)%, 3.9 (0.4)%, 2.4 (0.3)% and 1.3 (0.3%) (P < 0.001), but not lower limb BMD. Serum testosterone, PSA and haemoglobin levels decreased by 93.3 (0.4)%, 98.2 (0.5)%, and 8.8 (0.9)% (P < 0.001), respectively. In addition, physical activity levels decreased and levels of fatigue increased.
CONCLUSION
After 36 weeks of ADT there was a significant decrease in whole‐body and regional LM and bone mass, while whole‐body and regional FM increased in older men with prostate cancer. Strategies to counteract changes in soft tissue and bone mass during ADT should be formulated to minimize the risk of sarcopenia, osteoporosis and obesity.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18336606</pmid><doi>10.1111/j.1464-410X.2008.07539.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2008-07, Vol.102 (1), p.44-47 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69223469 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Absorptiometry, Photon Adipose Tissue - drug effects Adult Age Factors Aged Aged, 80 and over Androgen Antagonists - adverse effects androgen deprivation therapy Androgens - metabolism Antineoplastic Agents, Hormonal - adverse effects Biological and medical sciences Body Composition - drug effects Body Mass Index Bone Density - drug effects bone mass Cohort Studies fat mass Gynecology. Andrology. Obstetrics Humans lean mass Male Male genital diseases Medical sciences Middle Aged Muscle, Skeletal - drug effects Nephrology. Urinary tract diseases Prostate-Specific Antigen - blood Prostatic Neoplasms - complications Prostatic Neoplasms - drug therapy Quality of Life Risk Factors Testosterone - metabolism Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T05%3A06%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20muscle,%20fat%20and%20bone%20mass%20after%2036%E2%80%83weeks%20of%20maximal%20androgen%20blockade%20for%20prostate%20cancer&rft.jtitle=BJU%20international&rft.au=Galv%C3%A3o,%20Daniel%20A.&rft.date=2008-07&rft.volume=102&rft.issue=1&rft.spage=44&rft.epage=47&rft.pages=44-47&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2008.07539.x&rft_dat=%3Cproquest_cross%3E69223469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69223469&rft_id=info:pmid/18336606&rfr_iscdi=true |